MX2022002949A - Composiciones y metodos para el tratamiento de enfermedades inflamatorias e inmunes. - Google Patents

Composiciones y metodos para el tratamiento de enfermedades inflamatorias e inmunes.

Info

Publication number
MX2022002949A
MX2022002949A MX2022002949A MX2022002949A MX2022002949A MX 2022002949 A MX2022002949 A MX 2022002949A MX 2022002949 A MX2022002949 A MX 2022002949A MX 2022002949 A MX2022002949 A MX 2022002949A MX 2022002949 A MX2022002949 A MX 2022002949A
Authority
MX
Mexico
Prior art keywords
compositions
treatment
methods
inflammatory
immune diseases
Prior art date
Application number
MX2022002949A
Other languages
English (en)
Inventor
Gregory Mckenzie
David N Cook
Julie E Button
Original Assignee
Prolacta Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prolacta Bioscience Inc filed Critical Prolacta Bioscience Inc
Publication of MX2022002949A publication Critical patent/MX2022002949A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)

Abstract

Se presentan aquí composiciones, métodos, estrategias, kits y artículos de fabricación que son provechosos, entre otras cosas, en el tratamiento o prevención de enfermedades o condiciones tales como las que pueden estar asociadas a inflamación, infección, alergia, disfunción inmune o disbiosis del microbioma intestinal. En algunos aspectos, la invención presenta una combinación sinérgica de prebióticos, por ej., una mezcla de oligosacáridos de leche humana y una cepa probiótica, tal como una cepa con capacidad para internalizar y consumir los prebióticos, por ej., B. longum subsp. infantis.
MX2022002949A 2019-09-24 2020-09-24 Composiciones y metodos para el tratamiento de enfermedades inflamatorias e inmunes. MX2022002949A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962905256P 2019-09-24 2019-09-24
US202063027739P 2020-05-20 2020-05-20
US202063028743P 2020-05-22 2020-05-22
US202063053224P 2020-07-17 2020-07-17
PCT/US2020/052501 WO2021061991A1 (en) 2019-09-24 2020-09-24 Compositions and methods for treatment of inflammatory and immune diseases

Publications (1)

Publication Number Publication Date
MX2022002949A true MX2022002949A (es) 2022-04-06

Family

ID=72896070

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002949A MX2022002949A (es) 2019-09-24 2020-09-24 Composiciones y metodos para el tratamiento de enfermedades inflamatorias e inmunes.

Country Status (12)

Country Link
US (1) US20230068960A1 (es)
EP (1) EP4034143A1 (es)
JP (1) JP2022548785A (es)
KR (1) KR20220066904A (es)
CN (1) CN114364389A (es)
AU (1) AU2020354581A1 (es)
BR (1) BR112022005578A2 (es)
CA (1) CA3151145A1 (es)
IL (1) IL291140A (es)
MX (1) MX2022002949A (es)
TW (1) TW202126317A (es)
WO (1) WO2021061991A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111235132A (zh) * 2019-12-23 2020-06-05 浙江工业大学 一种β-半乳糖苷酶、基因、工程菌及其应用
CN112458031B (zh) * 2020-12-23 2022-04-29 江南大学 一株源自白酒酿造窖泥的产乳酸型己酸菌及其应用
EP4277634A1 (en) * 2021-01-12 2023-11-22 Prolacta Bioscience, Inc. Synbiotic treatment regimens
WO2022263597A1 (en) * 2021-06-18 2022-12-22 Chr. Hansen A/S Compositions for increasing resilience towards bacterial infections
AU2022312701A1 (en) * 2021-07-13 2024-01-18 Ab-Biotics, S.A. Probiotic composition for the treatment of increased intestinal permeability
WO2023088470A1 (en) * 2021-11-22 2023-05-25 The Chinese University Of Hong Kong Probiotic compositions for treatment of hair loss
US20230190834A1 (en) * 2021-12-21 2023-06-22 Solarea Bio, Inc. Immunomodulatory compositions comprising microbial entities
KR102616020B1 (ko) * 2021-12-31 2023-12-22 매일유업 주식회사 모유 올리고당 혼합물을 유효성분으로 포함하는 장관면역 개선용, 장 염증 예방 또는 개선용 조성물
CN115029270B (zh) * 2022-06-21 2023-11-28 江南大学 一株能够降低肠道促炎细胞因子的清酒乳杆菌及其应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8204879D0 (sv) 1982-08-26 1982-08-26 Haessle Ab Novel chemical intermediates
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
FI90544C (fi) 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
SE9002043D0 (sv) 1990-06-07 1990-06-07 Astra Ab Improved method for synthesis
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
US5374730A (en) 1993-11-04 1994-12-20 Torcan Chemical Ltd. Preparation of omeprazole and lansoprazole
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6203797B1 (en) 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
EP1034787A1 (en) 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactobacillus strains preventing diarrhea caused by pathogenic bacteria
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US20020182243A1 (en) 2001-05-14 2002-12-05 Medo Elena Maria Method of producing nutritional products from human milk tissue and compositions thereof
BRPI0616323A2 (pt) 2005-09-20 2011-06-14 Prolacta Bioscience Inc mÉtodo para determinar se um fluido mamÁrio doado foi obtido a partir de um indivÍduo especÍfico
US9149052B2 (en) 2006-08-30 2015-10-06 Prolacta Bioscience, Inc. Methods of obtaining sterile milk and compositions thereof
US9084434B2 (en) 2006-09-27 2015-07-21 Little Calumet Holdings Llc Probiotic oral dosage forms
ES2633922T3 (es) 2006-11-29 2017-09-26 Prolacta Bioscience, Inc. Composiciones de leche humana y métodos para la preparación y uso de las mismas
WO2010065652A1 (en) 2008-12-02 2010-06-10 Prolacta Bioscience, Inc. Human milk permeate compositions and methods of making and using same
EP2658401A2 (en) * 2010-12-31 2013-11-06 Abbott Laboratories Human milk oligosaccharides to promote growth of beneficial bacteria
DK2479263T3 (da) 2011-01-20 2014-02-03 Jennewein Biotechnologie Gmbh Nye fucosyltransferaser og deres anvendelser
CN103958537A (zh) 2011-09-30 2014-07-30 格礼卡姆股份公司 Hmo核心结构的合成
WO2013139344A1 (en) 2012-03-20 2013-09-26 Glycom A/S Synthesis of the trisaccharide 3-o-fucosyllactose and intermediates thereof
WO2013182206A1 (en) 2012-06-08 2013-12-12 Glycom A/S Method for producing oligosaccharides and oligosaccharide glycosides by fermentation
US20150183816A1 (en) 2012-06-22 2015-07-02 Glycom A/S Modified galactooligosaccharides
EP2864344A4 (en) 2012-06-22 2015-12-23 Glycom As GALACTOSYL GLYCOSYLATED DISACCHARIDES, PROCESSES FOR THEIR PRODUCTION AND USE THEREOF IN CONSUMABLE PRODUCTS
EP2868206B1 (en) * 2012-07-05 2016-09-14 Centro Nacional De Tecnología Y Seguridad Alimentaria, Laboratorio Del Ebro Microparticles for the encapsulation of probiotics, preparation and uses thereof
WO2014135167A1 (en) 2013-03-08 2014-09-12 Glycom A/S Purification of oligosaccaharides by reversible derivatization
GB201306687D0 (en) 2013-04-12 2013-05-29 Glycom As Synthesis of sialylated/fucosylated oligosaccharides
GB201306689D0 (en) 2013-04-12 2013-05-29 Glycom As Synthesis of sialylated/fucosylated human milk oligosaccharides
EP3041947A4 (en) 2013-09-06 2017-07-26 Glycom A/S Fermentative production of oligosaccharides
EP3572520A1 (en) 2013-09-10 2019-11-27 Jennewein Biotechnologie GmbH Production of oligosaccharides
EP2857410A1 (en) 2013-10-04 2015-04-08 Jennewein Biotechnologie GmbH Process for purification of 2´-fucosyllactose using simulated moving bed chromatography
DK2896628T3 (en) 2014-01-20 2019-01-14 Jennewein Biotechnologie Gmbh Process for Effective Purification of Neutral Milk Oligosaccharides (HMOs) from Microbial Fermentation
PL2927316T3 (pl) 2014-03-31 2019-05-31 Jennewein Biotechnologie Gmbh Całkowita fermentacja oligosacharydów
CN106460024B (zh) 2014-06-27 2021-10-01 格礼卡姆股份公司 寡糖的制备
CN107949391B (zh) * 2015-05-14 2021-11-09 克雷斯顿沃控股公司 用于粪便菌群移植的组合物以及用于制备和使用它们的方法和用于递送它们的装置
EP3141610A1 (en) 2015-09-12 2017-03-15 Jennewein Biotechnologie GmbH Production of human milk oligosaccharides in microbial hosts with engineered import / export
WO2017101958A1 (en) 2015-12-18 2017-06-22 Glycom A/S Fermentative production of oligosaccharides
SG11201807809XA (en) * 2016-03-11 2018-10-30 Evolve Biosystems Inc A transient commensal microorganism for improving gut health
MX2019002924A (es) 2016-09-19 2019-10-14 Prolacta Bioscience Inc Composiciones purificadas de oligosacaridos de leche humana.
DK3315610T3 (da) 2016-10-29 2021-03-08 Jennewein Biotechnologie Gmbh Fremgangsmåde til fremstilling af fucosylerede oligosaccharider
EP3425052A1 (en) 2017-07-07 2019-01-09 Jennewein Biotechnologie GmbH Fucosyltransferases and their use in producing fucosylated oligosaccharides
EP3450443A1 (en) 2017-08-29 2019-03-06 Jennewein Biotechnologie GmbH Process for purifying sialylated oligosaccharides

Also Published As

Publication number Publication date
KR20220066904A (ko) 2022-05-24
IL291140A (en) 2022-05-01
AU2020354581A1 (en) 2022-03-03
CN114364389A (zh) 2022-04-15
EP4034143A1 (en) 2022-08-03
JP2022548785A (ja) 2022-11-21
US20230068960A1 (en) 2023-03-02
CA3151145A1 (en) 2021-04-01
WO2021061991A1 (en) 2021-04-01
TW202126317A (zh) 2021-07-16
BR112022005578A2 (pt) 2022-09-20

Similar Documents

Publication Publication Date Title
MX2022002949A (es) Composiciones y metodos para el tratamiento de enfermedades inflamatorias e inmunes.
CY1122306T1 (el) Συνθεσεις που περιλαμβανουν bakthpiaka στελεχη
CY1122148T1 (el) Συνθεσεις που περιεχουν βακτηριακα στελεχη
CY1121473T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CL2022000057A1 (es) Métodos y productos para el tratamiento de trastornos gastrointestinales
WO2019118515A3 (en) Compositions and methods for suppressing pathogenic organisms
IL291460A (en) Bacterial strains, their compositions and their use in the treatment of gastrointestinal disorders
MX2022011985A (es) Prebioticos para reducir el riesgo de obesidad mas tarde en la vida.
PH12018550110A1 (en) Novel probiotic bacterial strain of lactobacillus plantarum and compositions and uses thereof in the treatment of inflammation
BR112018015121A2 (pt) cepa bacteriana da espécie faecalibacterium prausnitzii cncm i-4573 para o tratamento e a prevenção da inflamação gastrointestinal
IL291445A (en) Bacterial strains, their compositions and their use in the treatment of gastrointestinal disorders
BR112017019468A2 (pt) composições que metabolizam ou sequestram monômeros de açúcar livres e seus usos
RU2019110063A (ru) ПРОБИОТИЧЕСКИЕ ШТАММЫ БАКТЕРИЙ, ОТНОСЯЩИХСЯ К РОДУ Bifidobacterium, И ПРОБИОТИЧЕСКИЕ ЭКСТРАКТЫ ЭТИХ КЛЕТОК (PCE), ОБЛАДАЮЩИЕ ИММУНОСТИМУЛИРУЮЩИМИ СВОЙСТВАМИ
MX2022000369A (es) Cepa bacteriana de bifidobacterium bifidum, las composiciones de la misma y usos relacionados.
MX2017007654A (es) Cepas probioticas con capacidad de absorber colesterol, métodos y usos de las mismas.
MX2020009733A (es) Composiciones.
MX2021003224A (es) Combinacion de probioticos para el tratamiento de trastornos gastrointestinales relacionados con la inflamacion.
WO2021004958A3 (en) Compositions comprising bacterial strains
MX2017007969A (es) Bacterias de acido lactico y su uso para el tratamiento de mastitis.
MX2020001632A (es) Composiciones que comprenden cepas bacterianas.
EP3833738A4 (en) PROBIOTIC BACTERIA ISOLATED FROM WOLVES AND RELATED COMPOSITIONS AND METHODS
MX2023008227A (es) Regimenes de tratamiento simbiotico.
AR122309A1 (es) Composiciones y métodos para el tratamiento de enfermedades inflamatorias e inmunes
MY193625A (en) Probiotic composition for treatment or prevention of high blood cholesterol
MX2020013860A (es) Composiciones probioticas y sus usos.